Showing results (151-160 of 179) with videos related to
Sort By:
Pageof 18
NPJ Vaccines|March 12, 2024
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine primingAllan C deCamp, Martin M Corcoran, William J Fulp, et al.Ebiomedicine|June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionKelly E Seaton, Yunda Huang, Shelly Karuna, et al.Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.Science Translational Medicine|April 19, 2023
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trialDavid Benkeser, David C Montefiori, Adrian B McDermott, et al.Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.Biorxiv : the Preprint Server for Biology|March 3, 2021
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variantsLingshu Wang, Tongqing Zhou, Yi Zhang, et al.Viruses|October 28, 2023
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 TrialYing Huang, Nima S Hejazi, Bryan Blette, et al.The Lancet. HIV|May 23, 2025
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adultsRichard L Wu, Katherine V Houser, Martin R Gaudinski, et al.Biorxiv : the Preprint Server for Biology|April 5, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.Pageof 18